[Previous] Asura & Quark 6.52 - PrintPlanet.com...

 [Next] Photo and Image Editing Apps for August 21 2010 - iSmashPhone ...

Some related posts from Technorati and Google.

[Gene Silencing News from GenomeWeb] Novartis Options Quark's Phase II p53 Inhibitor | Gene Silencing ...: Should Novartis exercise the option, it would assume all responsibility for QPI-1002, which is currently being tested by Quark in separate phase II studies as a prophylactic against acute kidney injury in patients undergoing cardiac surgery, and to prevent delayed graft function associated with kidney transplantation.

[News] Novartis options Quark program in $680M pact - FierceBiotech: Underscoring the rich potential of new siRNA therapeutics, Novartis has agreed to pay Quark Pharmaceuticals up to $680 million to nail the licensing rights to a new therapy for kidney-related diseases.

[World News] Article > Novartis buys option for Quark's siRNA kidney drug: Furthermore, emphasising the drug’s potential, he said the gene target of QPI-1002, p53, plays a major role in apoptotic cell death, and its temporary suppression rescues cells by preventing death in conditions of severe stress such as ischemia, “potentially opening opportunities for Novartis to novel treatments in additional indications”.

[thepharmaletter.com] Quark Pharma in option deal with Novartis that could earn it $670 ...: California, USA-based RNAi-based therapeutics specialist Quark Pharmaceuticals has granted Swiss drug major Novartis an option to obtain an exclusive worldwide license to develop and commercialize its p53 temporary inhibitor siRNA drug QPI-1002, currently the subject of a Phase II clinical trial.

[Biomed Middle East] Biomed Middle East » Silence Therapeutics announces partner ...: Silence Therapeutics plc (AIM: SLN), a leading international RNAi therapeutics company, is pleased to note that its partner, Quark Pharmaceuticals, Inc. (“Quark”), has announced the grant of an option to Novartis to obtain an exclusive worldwide license to develop and commercialise QPI-1002, a p53 temporary inhibitor siRNA drug which incorporates Silence’s AtuRNAi technology.

[Press Releases] Quark Pharmaceuticals and Major Pharmaceutical Company Enter into ...: Quark is currently conducting clinical trials of QPI-1007, its proprietary synthetic siRNA drug candidate for ocular neuroprotection. QPI-1007 utilizes a proprietary structure developed in collaboration with BioSpring GmbH that provides Quark with freedom to operate in the siRNA intellectual property arena and chemical modifications that are designed to preserve RNAi activity while ameliorating potential off-target and immunostimulatory effects of siRNAs.

[BioSmash] Novartis Takes Over Development of Quark's p53 Inhibitor | BioSmash: Quark, based just east of San Francisco, is a leader in the discovery and development of RNAi-based therapeutics, a technology that uses synthetic RNA to bind to specific regions of DNA thereby inhibiting gene expression. The company’s development platform is broad, targeting several tissues and organs including the eye, kidney, ear, lung, spinal cord and brain.

[Asia Press Release] Quark Pharmaceuticals and Major Pharmaceutical Company Enter i ...: Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that it has granted. Novartis an option to obtain an exclusive worldwide license to develop and .

[Pharmainfo.net] Silence Therapeutics' Partner Quark Signs Exclusive Option ...: 19 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN), a leading international RNAi therapeutics company, is pleased to note that its partner, Quark Pharmaceuticals, Inc. ("Quark"), has announced the grant of an option to Novartis to ...

[The Beauty Shop] The Beauty Shop » Blog Archive » Quark Signs $680M siRNA Drug Deal ...: Privately held Quark Pharmaceuticals Inc. stands to bank $680 million, including $10 million up front, under a deal granting Swiss pharma giant Novartis AG an option to obtain an exclusive worldwide license to develop and commercialize QPI-1002, an investigational p53 temporary inhibitor siRNA drug.

[The Big Red Biotech Blog] Biotech Deals This Week - The Big Red Biotech Blog: Novartis paid Quark $10 M for an option on its Phase II candidate, QPI-1002, an siRNA therapy targeting the p53 gene in kidney disease as reported in Fierce Biotech. Based on achievement of milestones, Quark could realize as much as .

[Proactiveinvestors' Blog] Golden Silence Prospers as Investors Digest Novartis Deal ...: The focus of the study will be QPI-1002, an experimental kidney drug discovered by Silence, but licensed to American firm Quark. The treatment is now being taken into phase II clinical trials.

[Best Stock Trades Blog | Stock Market Information] Covered Calls vs. Dividends - Option Trading For Income Investors: OUPblog » Blog Archive » The Price of Praise and Prizes, or ”¦ Ignoring Arms Control History Carries a Cost | The Foundry ”¦ Quark Nabs Novartis Option Deal | Xconomy; Price To Pay For Social Networking - Identity Theft | WATBlog.com ”¦ ...

[Gene Silencing News from GenomeWeb] Snapshot: Partnership Goals, Track Records in the RNAi/miRNA Space ...: Last year, Novartis agreed to extend the deal for a fifth and final year. Due to expire in October, the deal gives Novartis the option to buy non-exclusive access to Alnylam's RNAi platform for use in its internal programs.

[Your LCD TV Repair Hub] LCD Monitor Repair - Malfunctioning LCD Or Plasma TV - The Repair ...: Considering what is happening to our planet, I believe this is one of the most important considerations when you are trying to work the buy or repair dilemma. If it can be fixed, why not do it (actually, this goes for CRT TVs, too)?

Reflected tags on Technorati: Blog, Quark, Graphic Design Blog